Conditions: Asthma
Allocation:  | Intervention model: PARALLEL
Enrollment: 296
Healthy volunteers: no

Brief summary:
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma. The selection of the optimum dose(s) will be based on bronchodilator efficacy (how well it helps your breathing), safety evaluations and pharmacokinetic evaluations (the amount of the medication found in your blood).

Detailed description:

Arms:

Interventions: intervention 1: BI 1744 CL
Intervention descriptions: intervention 1: None

Protocol document: